Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

SBANE recognizes Isis Biopolymer with 2010 Rising Star Award

Isis Biopolymer has been awarded the 2010 Rising Star Award by SBANE (Smaller Business Association of New England). The Rising Star is a coveted annual award that honors innovative products and services offered by early-stage companies in New England.

19 May 2010

Significant proportion of men with ED exhibit early signs of CAD: Review

International experts are calling for all men experiencing impotence to undergo thorough medical assessments, after an extensive review showed that a significant proportion of men with erectile dysfunction exhibit early signs of coronary artery disease.

19 May 2010

i3 completes acquisition of ChinaGate

i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organization that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.

19 May 2010

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

It is time to reassess mental disorders, recognizing that these are disorders of brain circuits likely caused by development processes, according to a commentary in the May 19 issue of JAMA, a theme issue on mental health.

19 May 2010

30 percent risk of heart attack in Australians over 55

According to a new study researchers have warned that at least one in five Australians over the age of 55 have a 30 percent chance of suffering a potentially fatal heart attack or stroke in the next five years.

18 May 2010

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

KemPharm, Inc. today announced that it has entered into an exclusive Supply Agreement with Johnson Matthey Inc., for the manufacture of the active pharmaceutical ingredient (API), KP201, KemPharm's novel hydrocodone prodrug for acute pain. KP201 was identified utilizing KemPharm's proprietary ligand activated therapy (LAT) approach.

18 May 2010

UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems

Researchers will be exploring whether a new, very low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks, strokes and other cardiovascular problems across the world, in a major new international trial that launches today.

18 May 2010

Tests of kidney function, damage predict risk of death from cardiovascular diseases: Study

Common tests of kidney function and damage predict the risk of death from cardiovascular diseases and all causes, according to a paper from the Chronic Kidney Disease Prognosis Consortium, established last year by Kidney Disease: Improving Global Outcomes.

18 May 2010

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

ElexoPharm GmbH, Merck announce collaboration and exclusive worldwide license agreement

ElexoPharm GmbH announced today a collaboration and exclusive worldwide license agreement with Merck & Co., Inc. Whitehouse Station, New Jersey USA (also known as MSD outside of the US and Canada) through an affiliate to develop and commercialize novel candidates targeting aldosterone synthase for the potential treatment of cardiovascular disease.

17 May 2010

Polypill to be tested in new heart disease trial

17 May 2010

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Long-term, regular use of vitamin E in women 45 years of age and older may help decrease the risk of chronic obstructive pulmonary disease by about 10 percent in both smokers and non-smokers, according to a study conducted by researchers at Cornell University and Brigham and Women's Hospital.

17 May 2010

Better health care for the indigenous population

A report from Melbourne University says that Indigenous Australians are six times more likely than other Australians to be blind and more than a third of this population has never had an eye examination. Now a substantial number of optometrists will be sent to remote Aboriginal communities under a $6.5 million federal program.

16 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Lotus Pharmaceuticals first-quarter net income up 38%

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China today reported its financial results for the first quarter ended March 31, 2010.

15 May 2010

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced its first quarter financial results for 2010.

14 May 2010

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Interleukin Genetics, Inc. announced today financial and operational results for the first quarter ended March 31, 2010.

14 May 2010

GE Healthymagination Fund invests $5M in CardioDx

GE Healthcare, the healthcare business of GE and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

14 May 2010

ARCA biopharma regains compliance for continued listing on NASDAQ

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that it received notification from the NASDAQ Stock Market that the Company has demonstrated compliance with the minimum stockholders' equity requirement for the NASDAQ Global Market

13 May 2010

Amarin reports cash balance of $44 million for first-quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported selected financial results for the fiscal quarter ended March 31, 2010 and provided a progress update of the Company's ANCHOR and MARINE trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

13 May 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

SBANE recognizes Isis Biopolymer with 2010 Rising Star Award

Significant proportion of men with ED exhibit early signs of CAD: Review

i3 completes acquisition of ChinaGate

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

30 percent risk of heart attack in Australians over 55

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems

Tests of kidney function, damage predict risk of death from cardiovascular diseases: Study

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ElexoPharm GmbH, Merck announce collaboration and exclusive worldwide license agreement

Polypill to be tested in new heart disease trial

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Better health care for the indigenous population

Athersys presents data supporting MultiStem programs

Lotus Pharmaceuticals first-quarter net income up 38%

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

GE Healthymagination Fund invests $5M in CardioDx

ARCA biopharma regains compliance for continued listing on NASDAQ

Amarin reports cash balance of $44 million for first-quarter 2010

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Newsletters you may be interested in